Ascendis Pharma (ASND)
(Delayed Data from NSDQ)
$147.36 USD
+1.09 (0.75%)
Updated Sep 26, 2024 04:00 PM ET
After-Market: $144.43 -2.93 (-1.99%) 7:58 PM ET
3-Hold of 5 3
F Value B Growth F Momentum D VGM
Brokerage Reports
Ascendis Pharma A/S [ASND/]
Reports for Purchase
Showing records 161 - 180 ( 303 total )
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q4/FY20 Financials; On-Track to Execute on Key Milestones; Top Pick
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
2021 Preview: Key Catalysts, Positive Outlook & Top Pick
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
R&D Oncology Day Showcases TC?s Broad Platform Potential; Clinical Data in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q3 Financials; TC-hGH/GHD MAA Validated; Next - Oncology R-D Day on Nov 20
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Six-Month OLE Data Clears the PaTHway for TC-PTH/HP Phase 3 in 2021
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
e-ECE Preview; TC-hGH/GHD PDUFA Set to June 25, 2021 and No AdComm
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q2- Cash Rich; TC-hGH BLA Accepted; New SF-36? Data Reinforces TC-PTH Benefit
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Strong Cash Position; TC-hGH Receives Positive Opinion from EMA PDCO for PIP
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
BLA Submitted; We Expect BLA Acceptance for Review in August
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Promising Preclinical TC IL-2 a/? Data at AACR; GHD BLA Submission in Q2
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Company: Ascendis Pharma A/S
Industry: Medical - Biomedical and Genetics
Q1; AACR Preview - On-Track to Submit TC-hGH BLA in Q2 and MAA in Q3
Provider: WEDBUSH SECURITIES INC.
Analyst: MOUSSATOS L